On 29 October 2025, EuroGCT participated in the “Building Bridges for Medicines Justice” conference at the University of Amsterdam, hosting a workshop titled "Is the EU Regulation on HTA Enhancing Equitable Access to Innovative Medicines in Europe? A EuroGCT workshop"
The workshop explores the challenges of enabling equitable patient access to Advanced Therapy Medicinal Products (ATMPs) like gene and cell therapies in the EU. Even when these therapies have central EU authorisation, high costs and differences in how each country decides which treatments to fund can lead to inconsistent access for patients. The workshop formed part of EuroGCT’s Regulatory Engagement Strategy, supporting our mission to connect researchers, regulators, and stakeholders to advance equitable access to gene and cell therapies in Europe.
presentation:
Equitable access to ATMPs in the Netherlands: Impact of the EU regulation and the BENELUXA initiative on HTA
Speaker: Dr. Lisette Vernooij
Dr. Lisette Vernooij is senior advisor European joint clinical assessments of medicinal products at the National Health Care Institute in the Netherlands. She has a PhD in epidemiology. Lisette is a JCA subgroup member and author on one of the ongoing JCAs together with Denmark.
Please download and view the PDF file of this presentation from the attachment section below.